CAR T-Cell Therapy During the COVID-19 Pandemic

This OncLive^® webinar will focus on the impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.

Topics:

• Resources for safe administration of CAR T-cell therapy
• Patient selection for the receipt of CAR T-cell therapy in the COVID-19 setting
• Supportive care and services for patients receiving therapy during the COVID-19 pandemic
• Impact on the continuation and enrollment of clinical trials involving CAR T-cell therapies and implications for patients

Sponsored by: Novartis

Novartis